New paradigm shift in the pharmacotherapy for heart failure-where are we now and where are we heading?

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Standard heart failure (HF) treatments for reduced ejection fraction (EF) include ACE inhibitors/ARBs, beta-blockers, and MRAs.
• Recent clinical trials have introduced novel therapeutic classes, altering established HF management strategies.
• Significant unmet needs persist, particularly in treating patients with preserved ejection fraction (HFpEF).

Purpose of the Study:

• To review paradigm shifts in HF pharmacotherapy over the last decade.
• To discuss emerging HF treatments and their impact on clinical practice.
• To propose a new therapeutic algorithm for managing patients with heart failure.

Main Methods:

• Review of large-scale clinical trials and guideline updates in heart failure management.
• Analysis of novel drug classes and their efficacy in different HF phenotypes.
• Synthesis of current evidence to inform updated treatment recommendations.

Main Results:

• Introduction of angiotensin receptor-neprilysin inhibitors (ARNIs), SGLT2 inhibitors, and ivabradine as key advancements.
• Evidence suggesting benefit from certain agents in patients with preserved ejection fraction (HFpEF).
• Emergence of soluble guanylate cyclase stimulators and omecamtiv mecarbil as potential next-generation therapies.

Conclusions:

• The treatment landscape for heart failure has evolved significantly, incorporating new drug classes.
• A personalized therapeutic approach is increasingly important, considering EF status and patient characteristics.
• Updated treatment algorithms are necessary to integrate these paradigm shifts into clinical practice for improved HF outcomes.